Physician profile
Hammad A Bhatti
NPI 1285953877
$41,355.54
in general payments reported to CMS, 2019-2025
11 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,535 · 2021: $11K · 2022: $4,204 · 2023: $2,423 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,320 · Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,320.00 |
| Food and Beverage | $874.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40,646.81 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $228.35 | 2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $196.47 | 2025 | Nucala, Trelegy Ellipta |
| Boston Scientific Corporation | $61.35 | 2025 | Farapulse |
| Insmed, INC. | $51.89 | 2025 | Arikayce |
| United Therapeutics Corporation | $43.89 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $33.25 | 2025 | Dupixent |
| Genzyme Corporation | $31.36 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.79 | 2025 | Glassia |
| Verona Pharma, INC. | $19.72 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $17.66 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.